PF-00489791 / Pfizer - LARVOL DELTA

Effect of long and short half-life PDE5 inhibitors on HbA1c levels: a systematic review and meta-analysis. (PubMed, EClinicalMedicine) - "Among 1096 studies identified, in analysis of 13 studies with 1083 baseline patients, long half-life PDE5 inhibitors (tadalafil, PF-00489791) had decreases in HbA1c while short half-life PDE5 inhibitors (sildenafil, avanafil) had no change. This suggests future investigation into PDE5 inhibitors as part of combination therapy or as therapy for high HbA1c individuals is needed, especially because of variable risk of biases, homogeneity, and sample sizes in our study. None."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. (PubMed, Cochrane Database Syst Rev) - "Based on low-certainty evidence, PDE5i may reduce the frequency of attacks of Raynaud's phenomenon by a small amount per week, result in a small reduction in the duration of attack, improve patients' global assessment of their disease, and result in little to no difference in pain. PDE5i probably result in little or no difference in serious adverse events but slightly increase the likelihood of withdrawing from treatment due to an adverse event."

Journal • Review • Cardiovascular • Fibrosis • Gastrointestinal Disorder • Immunology • Pain • Rheumatology • Scleroderma • Systemic Sclerosis

A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia (clinicaltrials.gov) - P2; N=72; Completed; Sponsor: Pfizer; N=130 ➔ 72

Enrollment change • Neuralgia • Pain • Peripheral Neuropathic Pain

Vasodilators for primary Raynaud's phenomenon. (PubMed, Cochrane Database Syst Rev) - "The included studies investigated several different vasodilators (topical and oral) for treatment of primary Raynaud's phenomenon. Small sample sizes, limited data, and variability in outcome reporting yielded evidence of very low to moderate certainty. Evidence is insufficient to support the use of vasodilators and suggests that vasodilator use may even worsen disease."

Journal • Review • Pain